Suppr超能文献

伴同侧锁骨上或内乳淋巴结转移的乳腺癌患者的预后。

Outcomes of patients with breast cancer who present with ipsilateral supraclavicular or internal mammary lymph node metastases.

机构信息

Division of Medical Senology, European Institute of Oncology, Milan, Italy.

Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.

出版信息

Clin Breast Cancer. 2014 Feb;14(1):53-60. doi: 10.1016/j.clbc.2013.09.008. Epub 2013 Sep 27.

Abstract

BACKGROUND

The prognostic implications of internal mammary (IM) and supraclavicular (SC) node involvement in locally advanced breast cancer is still unclear.

PATIENTS AND METHODS

We evaluated 107 patients with IM (n = 65) or SC (n = 42) node involvement who underwent operation at the European Institute of Oncology between 1997 and 2009 to assess their prognostic features. We subsequently analyzed matched cohorts, using the 107 patients as cases and another group of patients as a control cohort, to evaluate prognostic differences between patients with and those without IM or SC node involvement.

RESULTS

Five-year disease-free survival (DFS) was 84% in IM vs. 38.8% in SC node involvement (P < .0001), and 5-year overall survival (OS) was 96.9% in IM node vs. 57.1% in SC node involvement (P < .0001). No difference in outcome was found between patients with and controls without IM node involvement. Conversely, a statistically significant difference in DFS and locoregional recurrence was observed in patients with SC node involvement compared with controls without SC node involvement.

CONCLUSION

SC node involvement correlated with a significantly poorer outcome in patients with locally advanced breast cancer. Adequate staging, including biopsy of suspicious locoregional ipsilateral lymph nodes, is mandatory in these patients. Patients with IM or SC node involvement should be treated with curative intent using combined-modality treatments.

摘要

背景

局部晚期乳腺癌中内乳(IM)和锁骨上(SC)淋巴结受累的预后意义仍不清楚。

患者和方法

我们评估了 1997 年至 2009 年间在欧洲肿瘤研究所接受手术的 107 例 IM(n=65)或 SC(n=42)淋巴结受累患者,以评估其预后特征。随后,我们使用这 107 例患者作为病例,并将另一组患者作为对照队列,分析匹配队列,以评估有和无 IM 或 SC 淋巴结受累患者之间的预后差异。

结果

IM 组的 5 年无病生存率(DFS)为 84%,而 SC 淋巴结受累组为 38.8%(P<0.0001),IM 组的 5 年总生存率(OS)为 96.9%,而 SC 淋巴结受累组为 57.1%(P<0.0001)。有和无 IM 淋巴结受累的患者之间的结果无差异。相反,与无 SC 淋巴结受累的对照组相比,有 SC 淋巴结受累的患者在 DFS 和局部区域复发方面存在统计学显著差异。

结论

SC 淋巴结受累与局部晚期乳腺癌患者的预后显著恶化相关。在这些患者中,必须进行充分的分期,包括可疑局部同侧淋巴结的活检。有 IM 或 SC 淋巴结受累的患者应采用联合治疗方法进行治愈性治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验